Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment

Respiratory Medicine

Volumn 153, Issue , 2019, Pages 44-51

  Nathan, Steven D ^a   Costabel, Ulrich ^b   Albera, Carlo ^c   Behr, Jürgen ^d   Wuyts, Wim A ^e   Kirchgaessler, Klaus Uwe ^f   Stauffer, John L ^g   Morgenthien, Elizabeth ^g   Chou, Willis ^g   Limb, Susan L ^g   Noble, Paul W ^h  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b RUHRLANDKLINIK   (Germany)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITY OF MUNICH   (Germany)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f F HOFFMANN LA ROCHE LTD   (Switzerland)

^g GENENTECH INC   (United States)

^h CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Dyspnoea; Idiopathic pulmonary fibrosis; Mortality; Pirfenidone

Indexed keywords

CARBON MONOXIDE; PIRFENIDONE; PLACEBO; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDONE DERIVATIVE;

ADULT; AGED; ALL CAUSE MORTALITY; ANGINA PECTORIS; ANOREXIA; ARTICLE; BACKACHE; BODY WEIGHT DISORDER; BODY WEIGHT LOSS; BRONCHITIS; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; EXERCISE; FATIGUE; FEMALE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HEADACHE; HUMAN; INSOMNIA; LUNG DIFFUSION CAPACITY; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY RISK; NAUSEA; PERIPHERAL EDEMA; PNEUMONIA; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RESPIRATORY FAILURE; RHINOPHARYNGITIS; SIX MINUTE WALK TEST; STOMACH DISCOMFORT; UPPER RESPIRATORY TRACT INFECTION; VIRAL GASTROENTERITIS; WALKING DISTANCE; CASE CONTROL STUDY; CLINICAL TRIAL; DRUG EFFECT; EXERCISE TOLERANCE; HOSPITALIZATION; LUNG FUNCTION TEST; METABOLISM; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VERY ELDERLY; VITAL CAPACITY;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARBON MONOXIDE; CASE-CONTROL STUDIES; DYSPNEA; EXERCISE TOLERANCE; FEMALE; HOSPITALIZATION; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE; MIDDLE AGED; MORTALITY; PLACEBOS; PULMONARY DIFFUSING CAPACITY; PYRIDONES; RESPIRATORY FUNCTION TESTS; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 85067939114     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2019.04.016     Document Type: Article

References (29)

1. Meltzer, E.B., Noble, P.W., Idiopathic pulmonary fibrosis. Orphanet J. Rare Dis., 3, 2008, 8.
2. Nathan, S.D., Shlobin, O.A., Weir, N., Ahmad, S., Kaldjob, J.M., Battle, E., Sheridan, M.J., du Bois, R.M., Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. Chest 140:1 (2011), 221–229.
3. Raghu, G., Collard, H.R., Egan, J.J., Martinez, F.J., Behr, J., Brown, K.K., Colby, T.V., Cordier, J.F., Flaherty, K.R., Lasky, J.A., Lynch, D.A., Ryu, J.H., Swigris, J.J., Wells, A.U., Ancochea, J., Bouros, D., Carvalho, C., Costabel, U., Ebina, M., Hansell, D.M., Johkoh, T., Kim, D.S., King, T.E. Jr., Kondoh, Y., Myers, J., Müller, N.L., Nicholson, A.G., Richeldi, L., Selman, M., Dudden, R.F., Griss, B.S., Protzko, S.L., Schünemann, H.J., ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis, an official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 183:6 (2011), 788–824.
4. Ley, B., Collard, H.R., King, T.E. Jr., Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 183:4 (2011), 431–440.
5. European Medicines Agency, Summary of Product Characteristics - Esbriet (Pirfenidone). 2018 http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002154/human_med_001417.jsp&mid=WC0b01ac058001d124. (Accessed 25 February 2019)
6. European Medicines Agency, Summary of Product Characteristics - Ofev (Nintedanib). 2018 http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003821/human_med_001834.jsp&mid=WC0b01ac058001d124. (Accessed 25 February 2019)
7. Food and Drug Administration, Highlights of Prescribing Information - Esbriet. 2017 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208780s000lbl.pdf. (Accessed 25 February 2019)
8. Food and Drug Administration, Highlights of Prescribing Information - Ofev. 2018 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/205832s009lbl.pdf. (Accessed 25 February 2019)
9. Noble, P.W., Albera, C., Bradford, W.Z., Costabel, U., du Bois, R.M., Fagan, E.A., Fishman, R.S., Glaspole, I., Glassberg, M.K., Lancaster, L., Lederer, D.J., Leff, J.A., Nathan, S.D., Pereira, C.A., Swigris, J.J., Valeyre, D., King, T.E. Jr., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur. Respir. J. 47:1 (2016), 243–253.
10. Richeldi, L., du Bois, R.M., Raghu, G., Azuma, A., Brown, K.K., Costabel, U., Cottin, V., Flaherty, K.R., Hansell, D.M., Inoue, Y., Kim, D.S., Kolb, M., Nicholson, A.G., Noble, P.W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., Stowasser, S., Schlenker-Herceg, R., Disse, B., Collard, H.R., INPULSIS Trial Investigators, Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 370:22 (2014), 2071–2082.
11. King, T.E. Jr., Bradford, W.Z., Castro-Bernardini, S., Fagan, E.A., Glaspole, I., Glassberg, M.K., Gorina, E., Hopkins, P.M., Kardatzke, D., Lancaster, L., Lederer, D.J., Nathan, S.D., Pereira, C.A., Sahn, S.A., Sussman, R., Swigris, J.J., Noble, P.W., ASCEND Study Group, A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 370:22 (2014), 2083–2092.
12. Noble, P.W., Albera, C., Bradford, W.Z., Costabel, U., Glassberg, M.K., Kardatzke, D., King, T.E. Jr., Lancaster, L., Sahn, S.A., Szwarcberg, J., Valeyre, D., du Bois, R.M., CAPACITY Study Group, Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 377:9779 (2011), 1760–1769.
13. Russell, A.M., Ripamonti, E., Vancheri, C., Qualitative European survey of patients with idiopathic pulmonary fibrosis: patients' perspectives of the disease and treatment. BMC Pulm. Med., 16, 2016, 10.
14. Nathan, S.D., Albera, C., Bradford, W.Z., Costabel, U., du Bois, R.M., Fagan, E.A., Fishman, R.S., Glaspole, I., Glassberg, M.K., Glasscock, K.F., King, T.E. Jr., Lancaster, L., Lederer, D.J., Lin, Z., Pereira, C.A., Swigris, J.J., Valeyre, D., Noble, P.W., Wells, A.U., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. Thorax 71:5 (2016), 429–435.
15. Nathan, S., Costabel, U., Albera, C., Kirchgaessler, K.-U., Chou, W., Noble, P.W., Effect of pirfenidone on all-cause mortality (ACM)and forced vital capacity (FVC)in idiopathic pulmonary fibrosis (IPF)patients with low FVC and/or low DLco: analysis of pooled data from ASCEND and CAPACITY. Am. J. Respir. Crit. Care Med., 195, 2017, A5390.
16. Hankinson, J.L., Odencrantz, J.R., Fedan, K.B., Spirometric reference values from a sample of the general U.S. population. Am. J. Respir. Crit. Care Med. 159:1 (1999), 179–187.
17. Crapo, R.O., Morris, A.H., Standardized single breath normal values for carbon monoxide diffusing capacity. Am. Rev. Respir. Dis. 123:2 (1981), 185–189.
18. Noble, P., Albera, C., Chou, W., Costabel, U., Day, B.-M., Glaspole, I., Glassberg, M., Lancaster, L., Lederer, D., Nathan, S., Pereira, C., Stauffer, J., Swigris, J., Annual rate of FVC decline in patients with IPF treated with pirfenidone: pooled analysis from 3 pivotal studies. Eur. Respir. J., 48(Suppl 60), 2016, OA1810.
19. Nathan, S.D., Albera, C., Bradford, W.Z., Costabel, U., Glaspole, I., Glassberg, M.K., Kardatzke, D.R., Daigl, M., Kirchgaessler, K.U., Lancaster, L.H., Lederer, D.J., Pereira, C.A., Swigris, J.J., Valeyre, D., Noble, P.W., Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. Lancet Respir. Med. 5:1 (2017), 33–41.
20. Aragaki-Nakahodo, A.A., Baughman, R.P., Shipley, R.T., Benzaquen, S., The complimentary role of transbronchial lung cryobiopsy and endobronchial ultrasound fine needle aspiration in the diagnosis of sarcoidosis. Respir. Med. 131 (2017), 65–69.
21. Ogura, T., Azuma, A., Inoue, Y., Taniguchi, H., Chida, K., Bando, M., Niimi, Y., Kakutani, S., Suga, M., Sugiyama, Y., Kudoh, S., Nukiwa, T., All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis. Respir. Investig. 53:5 (2015), 232–241.
22. Sakamoto, S., Itoh, T., Muramatsu, Y., Satoh, K., Ishida, F., Sugino, K., Isobe, K., Homma, S., Efficacy of pirfenidone in patients with advanced-stage idiopathic pulmonary fibrosis. Intern. Med. 52:22 (2013), 2495–2501.
23. Costabel, U., Albera, C., Kirchgaessler, K.-U., Gilberg, F., Petzinger, U., Noble, P., Analysis of patients with idiopathic pulmonary fibrosis (IPF)with percent predicted forced vital capacity (FVC)<50% treated with pirfenidone (PFD)in RECAP. Eur. Respir. J., 48(Suppl 60), 2016, OA1813.
24. Wuyts, W.A., Kolb, M., Stowasser, S., Stansen, W., Huggins, J.T., Raghu, G., First data on efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis and forced vital capacity of ≤50 % of predicted value. Lung 194:5 (2016), 739–743.
25. Lancaster, L., Albera, C., Bradford, W.Z., Costabel, U., du Bois, R.M., Fagan, E.A., Fishman, R.S., Glaspole, I., Glassberg, M.K., King, T.E. Jr., Lederer, D.J., Lin, Z., Nathan, S.D., Pereira, C.A., Swigris, J.J., Valeyre, D., Noble, P.W., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials. BMJ Open Respir. Res., 3(1), 2016, e000105.
26. Maher, T., Cottin, V., Azuma, A., Groves, L., Hormel, P., Skold, M., Tomassetti, S., Koschel, D., Pirfenidone Post-authorization Safety Registry (PASSPORT)– Update and Concomitant Use of NAC And/or Corticosteroids. 2015, British Thoracic Society Winter Meeting.
27. Hutchinson, J., Fogarty, A., Hubbard, R., McKeever, T., Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur. Respir. J. 46:3 (2015), 795–806.
28. Flaherty, K.R., Fell, C.D., Huggins, J.T., Nunes, H., Sussman, R., Valenzuela, C., Petzinger, U., Stauffer, J.L., Gilberg, F., Bengus, M., Wijsenbeek, M., Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis. Eur. Respir. J., 52(2), 2018, 1800230.
29. Vancheri, C., Kreuter, M., Richeldi, L., Ryerson, C.J., Valeyre, D., Grutters, J.C., Wiebe, S., Stansen, W., Quaresma, M., Stowasser, S., Wuyts, W.A., INJOURNEY trial investigators, nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis: results of the INJOURNEY trial. Am. J. Respir. Crit. Care Med. 197:3 (2018), 356–363.